Revolution Medicines Secures $2B Funding from Royalty Pharma for RAS Cancer Drugs as Biotech Sector Heats Up
Revolution Medicines Secures $2B Funding from Royalty Pharma for RAS Cancer Drugs as Biotech Sector Heats Up
Revolution Medicines announced a $2 billion flexible funding agreement with Royalty Pharma on June 24, 2025, including up to $1.25B in synthetic royalties on daraxonrasib sales and $750M in debt. 1 2 The deal supports independent global development and commercialization of RAS(ON) inhibitors like daraxonrasib for NSCLC and PDAC, without needing a Big Pharma partner. 1 2 Revolution received the first $250M tranche immediately, with more tied to milestones like Phase 3 PDAC study success; royalties start at 4.55% on first $2B sales. 1 2 Company ended March with $2.1B cash, now extending runway significantly and pursuing global commercialization strategy. 1 2 Query mentions XBI reaching pandemic highs, signaling strong biotech market sentiment amid this financing news, though specifics on XBI not detailed in sources. 6 Sources: 1. https://www.fiercebiotech.com/biotech/royalty-signs-2b-bankroll-revolutions-ras-cancer-drugs-road-approval 2. https://www.biospace.com/press-relea...
- Get link
- X
- Other Apps